Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

38.83 +0.27 (+0.70%)
Streaming Delayed Price Updated: 10:48 AM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 510,664
Open 38.84
Bid (Size) 38.82 (16)
Ask (Size) 38.83 (2)
Prev. Close 38.56
Today's Range 38.77 - 39.03
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
From GSK plc
Via Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace

Performance

YTD
+3.52%
+3.52%
1 Month
-5.96%
-5.96%
3 Month
-4.57%
-4.57%
6 Month
-2.90%
-2.90%
1 Year
+13.80%
+13.80%

More News

Read More
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
Via Benzinga
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
Via InvestorPlace
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Via Benzinga
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
Via Benzinga
Topics ETFs
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Via Benzinga
Exposures COVID-19
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
Via The Motley Fool
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
Via Benzinga
Why Is Moderna Stock Trading Lower On Wednesday?
Via Benzinga
Exposures COVID-19
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
Via Investor's Business Daily
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Via Benzinga
UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Via Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Via Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Via InvestorPlace
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
Via Investor's Business Daily
Exposures COVID-19
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.